Thomas K Equels, CEO & President at AIM ImmunoTech, bought AIM on Sep 16, 2026
Data as of Oct 16
- Traded
- Sep 16, 2026
- Disclosed
- Sep 17, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
AIM since disclosure
−22.6%
Similar stocks (SPY) since disclosure
+0.1%
S&P 500 (SPY)
Change in closing price from Sep 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.